IMMUNOTHERAPY

Andre Goy, MD, from John Theurer Cancer Center, discusses recent research into fighting cancer with the immune system.

A phase III study of Revlimid in combination with dexamethasone in patients with newly diagnosed multiple myeloma met its primary endpoint of PFS.

The next-generation PI3 kinase (PI3K) inhibitor GDC-0032 has shown signs of efficacy in patients with advanced cancers that were mutated for the PI3K alpha gene.

The anti-PD-1 therapy nivolumab demonstrated an overall objective response rate of 31%, with a median duration of 2 years in patients with advanced melanoma.

Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from a phase I trial investigating the anti-PD-1 monoclonal antibody nivolumab.

The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.

In advance of the 2013 ASCO Annual Meeting, Targeted Healthcare spoke with Mike Thompson, MD, PhD, about the use of social media in the field of oncology.

Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.

Andrew T. Parsa MD, PhD, describes the development and trial involving prophage G-200, a vaccine for recurrent glioblastoma multiforme.

Roy S. Herbst, MD, PhD, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer.

Clifford A. Hudis, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Lenalidomide has been approved to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.

In the wake of the approval of several novel treatments for prostate cancer, physicians must now focus on how best to integrate new therapies into the treatment of patients with prostate cancer.

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, gives an overview of the treatment of advanced melanoma at the 2013 ASCO Annual Meeting.

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the mechanisms of resistance in breast cancer.

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, discusses the use of pomalidomide in relapsed or refractory multiple myeloma.

Meletios A. Dimopoulos, MD, Alexandra Hospital, Athens, Greece, explains a phase III study that analyzed pomalidomide in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.